Europe Faces Criticism for Potential Mpox Vaccine Hoarding as Africa Struggles

As the mpox outbreak intensifies in Africa, concerns are rising that Europe might repeat its Covid-19 vaccine hoarding mistakes, leaving African nations without sufficient doses. While Europe has pledged hundreds of thousands of doses, experts believe Africa needs significantly more, with the DRC alone requiring 3.5 million doses. Despite pledges, evidence suggests Europe is holding onto millions of doses, raising ethical questions about vaccine distribution.

Mpox: Global Health Challenge and Ongoing Research

Mpox, previously known as monkeypox, has transitioned from a regional disease in Africa to a global health concern. This article explores the recent developments, risk factors, diagnostic methods, treatment options, and ongoing research related to Mpox. It also discusses the role of vaccines, the emergence of new variants, and the ongoing efforts by the WHO to control the outbreak.

Thailand Reports Suspected First Case of More Dangerous Mpox Strain

Thailand is investigating a suspected case of the more dangerous Clade 1 mpox strain in a European traveler who arrived from an African country. This comes as the WHO declared a global public health emergency due to the recent surge in mpox cases and deaths, particularly in Africa. While laboratory tests are ongoing, officials are confident that the patient is infected with the Clade 1 variant, which is associated with a higher fatality rate.

Deadly New Mpox Strain Spreads, Prompting Global Response

A new, more transmissible and severe strain of mpox (Clade I) has emerged in Africa and is spreading globally, prompting authorities in Europe, China, and other countries to intensify screening efforts. The World Health Organization has declared mpox a global health emergency, and vaccine donations are being coordinated. The new strain has been confirmed in Sweden, and Pakistan is conducting sequencing to determine if it is the new strain. While the risk to the public in the US is considered low, healthcare providers are being advised to be vigilant.

Virax Biolabs Stock Soars on Mpox Concerns: How to Invest

Virax Biolabs Group Limited (VRAX) shares surged on Monday as investors seek exposure to companies developing treatments for mpox, following the World Health Organization’s declaration of a global health emergency last week. The company’s focus on diagnostics and a potential T-Cell Test for mpox has attracted investor attention. This article explores how to invest in Virax Biolabs and provides insights into the current market dynamics.

India on High Alert for Mpox as WHO Declares Public Health Emergency

Following the World Health Organisation’s declaration of Mpox as a Public Health Emergency, India has taken precautionary measures, including heightened surveillance at airports and land borders, to prevent the spread of the virus. While no cases have been reported in the country, India is closely monitoring the situation and has designated hospitals for managing potential cases.

GeoVax Labs (GOVX) Stock Surges Over 225% on Mpox Concerns

GeoVax Labs Inc (GOVX) shares have surged over 225% in the past week, driven by heightened investor interest in mpox (monkeypox) related stocks. This surge follows the World Health Organization’s declaration of a public health emergency due to the mpox outbreak in Africa. GeoVax, a clinical-stage biotechnology company developing vaccines against infectious diseases, has previously published research suggesting its vaccines could help prevent mpox.

Mpox: Understanding the Virus and its Spread

This article explains what mpox is, how it spreads, and what precautions can be taken to prevent its transmission. It covers human-to-human transmission, animal-to-human transmission, and the potential for human-to-animal transmission. It also discusses the importance of avoiding close contact with infected individuals and animals, and the role of hygiene in preventing the spread of the virus.

Scroll to Top